Keywords: Presage Biosciences, Celgene, Collaboration, Drug combinations, Solid tumor indications

Presage Biosciences in deal with Celgene on novel cancer drug combinations

Article | 06 March 2013

Privately-held USA-based cancer drug developer Presage Biosciences has entered into a strategic collaboration with US biotech major Celgene (Nasdaq: CELG) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Celgene

Presage Biosciences

Go to company listing